Compare Oruka Therapeutics Inc. Common Stock (ORKA) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oruka Therapeutics Inc. Common Stock vs ProShares UltraPro Short QQQ ETF — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B), while ProShares UltraPro Short QQQ ETF trades at $37.19 (market cap $2.13B). The key difference: Oruka Therapeutics Inc. Common Stock is far larger — about 2.4× ProShares UltraPro Short QQQ ETF's market cap, and Oruka Therapeutics Inc. Common Stock is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and ProShares UltraPro Short QQQ ETF for 12 Days on average.
| ORKA | SQQQ | |
|---|---|---|
Market Cap | $5.18B | $2.13B |
Volume | 490,798 | 37,167,173 |
Sector | Health | Leveraged / Inverse |
52-Week High | $113.08 | $89.43 |
52-Week Low | $26.19 | $31.83 |
Typical Hold Time | 0 Days | 12 Days |
Enterprise Value | $4.31B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SQQQ, the ProShares UltraPro Short QQQ ETF, is currently trading at $33.98, up 1.04% on the day. The technical outlook is bearish, with moving averages signaling a downtrend and oscillators neutral. As a 3x leveraged inverse ETF, its performance is directly tied to declines in the Nasdaq-100 index. Recent news highlights its use as a hedging tool against tech sector weakness, with articles discussing its potential benefits amid concerns over the AI-fueled tech rally.
The outlook for SQQQ is inherently tied to market sentiment toward the Nasdaq-100. It presents a high-risk, tactical opportunity for investors seeking to profit from or hedge against a downturn in major technology stocks. Key risks include the daily reset mechanism of leveraged ETFs, which can lead to decay in volatile markets, and the potential for rapid losses if the tech rally resumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
